Want to see UNCY full AI Analyst Report?

Unicycive Therapeutics (UNCY) Price & Analysis

927 Followers

UNCY Stock Chart & Stats

$7.02

-$0.03(-4.01%)

At close: Jan 08 4:00 PM EST

$7.02

-$0.03(-4.01%)

Day’s Range― - ―

52-Week Range$3.71 - $8.74

Previous CloseN/A

Volume1.16M

Average Volume (3M)814.92K

Market Cap

$125.22M

Enterprise Value$115.08M

Total Cash (Recent Filing)$54.59M

Total Debt (Recent Filing)$941.00K

Price to Earnings (P/E)―

Beta1.65

Next Earnings

Aug 17, 2026

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.05

Shares Outstanding26,700,027

10 Day Avg. Volume1,053,209

30 Day Avg. Volume814,925

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)30.36

Price to Sales (P/S)0.00

P/FCF Ratio-29.25

Enterprise Value/Market Cap0.92

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-329.75

Enterprise Value/Ebitda-2.93

Forecast

1Y Price Target

$37.83

Price Target Upside438.94% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-1.43

Revenue Forecast (FY)$17.83M

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetVery low leverage and materially improved equity reduce insolvency risk and increase strategic optionality. A conservatively levered balance sheet supports remediation or partner negotiations, and provides a buffer to fund near-term regulatory activities or development milestones over the next several months.

Clinical Dataset De-riskedRegulator acceptance of the clinical safety and efficacy package removes core clinical risk for OLC and focuses outstanding review on manufacturing. With clinical data intact, successfully resolving manufacturing compliance materially increases approval odds and preserves the program's commercial potential.

Durable Financing FlexibilityAn enlarged at-the-market program and shelf registration provide ongoing, programmatic access to capital. This structural financing flexibility enables the company to fund manufacturing remediation, operations, or partnerships without needing a single large raise, supporting development continuity over months.

Bears Say

No Revenue / Sustained LossesThe company remains pre-revenue and materially loss-making, indicating no internal cash generation from products. Persistent net losses limit reinvestment capacity, lengthen time to self-sufficiency, and make the business dependent on external funding sources for program progression.

Deep Negative Free Cash FlowSignificant negative free cash flow shows ongoing cash burn that roughly tracks reported losses, but still requires fresh capital. Continued negative FCF constrains strategic choices, raises dilution risk, and could slow development if access to financing is curtailed or becomes more costly.

Manufacturing/regulatory Execution RiskThe FDA CRL stems from repeated third‑party manufacturing deficiencies and delays the application despite acceptable clinical data. Manufacturing compliance failures are structural execution risks that can prolong approval timelines, increase remediation costs, and potentially require vendor changes.

Unicycive Therapeutics News

Unicycive Therapeutics price target lowered to $50 from $60 at Noble Capital

Noble Capital lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $50 from $60 and keeps an...

15h ago

UNCY

Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark

Benchmark lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $13 from $18 and keeps a Speculative...

16h ago

UNCY

Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $15 from $22...

2d ago

UNCY

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

Unicycive Therapeutics (UNCY) announced it received a second FDA Complete Response Letter for its OLC NDA, again tied...

2d ago

UNCY

Morning Movers: Abivax skyrockets following new obefazimod data

Markets are ending the second quarter on a cautious note, with the indexes pointing slightly lower as investors...

2d ago

DLR

XYZ

Unicycive Therapeutics receives complete response letter from FDA for OLC NDA

Unicycive Therapeutics (UNCY) announced that it has received a complete response letter, or CRL, from the FDA regarding...

2d ago

UNCY

H.C. Wainwright recommends taking advantage of Unicycive stock weakness

Unicycive’s lead candidate oxylanthanum carbonate, a novel oral phosphate binder for hyperphosphatemia in CKD patients on dialysis, was...

6d ago

UNCY

Unicycive Therapeutics files $150M mixed securities shelf

16:18 EDT Unicycive Therapeutics (UNCY) files $150M mixed securities shelf Published first on TheFly – the ultimate source...

26d ago

UNCY

Unicycive Therapeutics price target raised to $18 from $15 at Benchmark

Benchmark raised the firm’s price target on Unicycive Therapeutics (UNCY) to $18 from $15 and keeps a Speculative...

30d ago

UNCY

Unicycive Expands At-The-Market Equity Offering Program

Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. Unicycive Therapeutics, Inc. expanded its existing at-the-market equity program...

26d ago

UNCY

Unicycive Therapeutics management to meet virtually with Piper Sandler

Virtual Meeting to be held on May 29 hosted by Piper Sandler. Published first on TheFly – the...

1M ago

UNCY

Ramakanth Reiterates Buy on Unicycive, Sees De-Risked Path to FDA Approval with 12-Month $22 Price Target Unchanged

Unicycive Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from...

1M ago

UNCY

UNCY Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Unicycive Therapeutics, Inc. (UNCY) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street...

3M ago

UNCY

3 Best Stocks to Buy Today, 3/18/2026, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

4M ago

UAL

EVMN

UNCY FAQ

What was Unicycive Therapeutics, Inc.’s price range in the past 12 months?

Unicycive Therapeutics, Inc. lowest stock price was $3.71 and its highest was $8.74 in the past 12 months.

What is Unicycive Therapeutics, Inc.’s market cap?

Unicycive Therapeutics, Inc.’s market cap is $125.22M.

When is Unicycive Therapeutics, Inc.’s upcoming earnings report date?

Unicycive Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 46 days.

How were Unicycive Therapeutics, Inc.’s earnings last quarter?

Unicycive Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.459 by -$0.081.

Is Unicycive Therapeutics, Inc. overvalued?

According to Wall Street analysts Unicycive Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Unicycive Therapeutics, Inc. pay dividends?

Unicycive Therapeutics, Inc. does not currently pay dividends.

What is Unicycive Therapeutics, Inc.’s EPS estimate?

Unicycive Therapeutics, Inc.’s EPS estimate is -0.52.

How many shares outstanding does Unicycive Therapeutics, Inc. have?

Unicycive Therapeutics, Inc. has 26,700,027 shares outstanding.

What happened to Unicycive Therapeutics, Inc.’s price movement after its last earnings report?

Unicycive Therapeutics, Inc. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.459. Following the earnings report the stock price went up 2.767%.

Which hedge fund is a major shareholder of Unicycive Therapeutics, Inc.?

Currently, no hedge funds are holding shares in UNCY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Unicycive Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-131.18%

Trailing 12-Months

Asset Growth

130.46%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Unicycive Therapeutics (UNCY) Earnings & Revenues

Historic Earnings Reports

UNCY Stock 12 Month Forecast

Average Price Target

$37.83

▲(438.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","25":"$25","47":"$47","69":"$69","91":"$91"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.83333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,25,47,69,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.69,11.252307692307692,17.814615384615387,24.37692307692308,30.93923076923077,37.50153846153846,44.06384615384616,50.62615384615385,57.18846153846154,63.75076923076923,70.31307692307692,76.87538461538462,83.43769230769232,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.69,7.239487179487179,9.78897435897436,12.338461538461537,14.887948717948717,17.437435897435897,19.986923076923077,22.536410256410257,25.085897435897436,27.635384615384616,30.184871794871796,32.734358974358976,35.28384615384615,{"y":37.83333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.69,5.32923076923077,5.968461538461539,6.607692307692307,7.246923076923077,7.886153846153846,8.525384615384615,9.164615384615384,9.803846153846154,10.443076923076923,11.082307692307692,11.721538461538461,12.360769230769229,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.77,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.99,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.67,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >